Life Sciences Industry Threatened by Skills Shortage

MARK TERRY | April 19, 2019 | 229 views

There is something of a recurring theme among the life science, healthcare and biopharma industries: a shortage of skilled employees will lead to a decrease in innovation. It’s not that the educational system is somehow letting these industries down, it’s more that these industries are changing so quickly, it’s difficult to keep up.

Spotlight

SiriusDecisions

SiriusDecisions® is the leading global b-to-b research and advisory firm. We deliver actionable intelligence, strategic and operational frameworks, and personal guidance from experienced practitioners. Sales, marketing and product executives rely on SiriusDecisions® to contextualize problems and bring to light opportunities to drive sustainable growth. Our holistic solutions are founded on proprietary research, a deep understanding of b-to-b complexities, and the tenet that organizational alignment brings better outcomes. SiriusDecisions was acquired by Forrester (NASD: FORR) in January of 2019.

OTHER ARTICLES
PHARMA TECH

3D Bioprinting Forefronts Technology in Pharmaceutical & Regenerative Medicine

Article | July 12, 2022

3D printing technology has emerged as a significant driver in the ongoing radical shift across several industrial domains' production processes. The incorporation of 3D printing into tissue engineering, through the use of life cells encapsulated in specialized synthetic or natural biomaterials (e.g. chitosan) as bioinks. This is laying the groundwork for numerous innovative solutions for healthcare and biomedical challenges, heralding new frontiers in medicine, pharmaceuticals, and biotechnology. 3D Bioprinting: A New Pathway in Medicine Additive manufacturing, which is the process of joining materials to create objects using computer-aided design (CAD) model data, such as 3D bioprinting, has the potential to disrupt the global pharmaceutical and regenerative medicine industry. Today, this technology has permeated countless industries, including pharmaceuticals, automobiles, dental, electronics, and others. The successful implementation of additive manufacturing in the healthcare sector has led to the development of surgical instruments, medical devices, and body implants. The past ten years have seen significant progress in the bioprinting arsenal, with many revolutionary and cutting-edge innovations, helping 3D bioprinting emerge as one of the most exciting and promising technologies. This advanced additive manufacturing has the potential to impact a wide variety of medical applications. Some of the applications making use of 3D bioprinting are Medical Education and Training Drug Delivery Manufacturing of Surgical Instruments Surgery Preparation Production of Personalized Prosthetics It has been estimated that 3D bioprinting in the medical field will be worth $3.8 billion by 2026, in comparison to the $1.4 billion registered in 2020. The domain’s compound annual growth rate is forecast to reach 18.2% between 2021 and 2026. The Way Ahead A large number of medical researchers and pharmaceutical companies are experimenting with printing de novo organs such as hearts, kidneys, livers, lungs, and skin, among others, to assist with the study of organs in-vitro, the development of drugs for specific diseases, and decrease the shortage of organs for transplant. For instance, Organovo, a medical laboratory and research company based in the United States, presented pre-clinical data for the functionality of its liver tissue in a program for type 1 tyrosinemia, a disease that makes it difficult for the body to metabolize the amino acid tyrosine. A multiplicity of such developments will increase the penetration of 3D bioprinting in the medical field, presenting opportunities for pharmaceutical leaders to invest in the domain.

Read More
PHARMA TECH

Biomaterials Emerging as a Blessing in the Pharmaceutical Industry

Article | September 29, 2022

Biomaterials are materials (natural or synthetic) that are biologically compatible with the human body and are used to replace, restore, support, or enhance the biological functions of damaged tissues while being in constant contact with body fluids. Over the past couple of decades, biomaterials have made their mark in the rapidly evolving pharmaceutical and medical fields. These materials are designed to interact with living biological tissue and are used for therapeutic and diagnostic purposes. Previously, biomaterials were only used in medical devices to replace or treat tissues or improve organ functions. However, it was later discovered that the term "non-viable" was inappropriate as biomaterials can be used for a variety of medical applications other than implanted devices. Growing Cases of Chronic Wounds Deepen the Penetration of Biomaterials There is a significant rise in the side effects caused due to the use of non-biocompatible materials for the treatment of chronic wounds caused by conditions such as malignant tumors, diabetes, infections, and vasculopathy, among others. Using biodegradable and biocompatible drug carriers is one way to avoid or reduce the side effects that may result from drug delivery to cells with enhanced efficiency and performance during the health rehabilitation process. Also, the use of biomaterials assists in enhancing chronic wound healing through anti-infection and antioxidant effects, immunoregulation, debridement, extracellular matrix remodeling, and angiogenesis, further increasing the adoption of pharmaceutical products made using these materials. Due to their favorable properties, biomaterials are gaining massive traction across the pharmaceutical industry. Here are some of the applications of biomaterials as follows. Dental Injectable Medical Implants Organ Regeneration (Heart, Lungs, Knee, Tracheal graft, others) Drug Delivery Regenerative Medicines Tissue Engineering Wound Healing Disease Treatment The Way Forward Leading manufacturers of biomaterials are aiming at expanding their biomaterial production capacity to strengthen their footprint and gain a competitive edge in the industry. For instance, in 2020, Evonik Industries AG, a German specialty chemicals company, announced the launch of a new biomaterial manufacturing facility in Birmingham, the U.S. to expand the company’s territory across North America. Following the trend, biomaterials are anticipated to create massive investment prospects for pharmaceutical players.

Read More
BUSINESS INSIGHTS

Use of AI: Reshaping the Pharmaceutical Industry

Article | June 30, 2022

For decades, the pharmaceutical industry has counted on state-of-the-art technologies to ensure the market entry of safe and dependable medications. The recent pandemic has shown how important it is for drug companies to get new drugs and vaccines on the market as soon as possible. The incorporation of artificial intelligence and machine learning technologies has greatly benefited the consumer healthcare business and the pharmaceutical industry. These technologies have been indispensable in the field of augmented intelligence, where they are used for applications such as disease detection and diagnosis, research and development, drug manufacturing, and others. How is AI Being Used Across the Pharmaceutical Sector? AI and ML are finding a plethora of applications across the pharmaceutical sector, starting from managing the process of clinical trial databases to drug discovery and disease diagnosis and treatment. These advanced technologies have further gained immense popularity with the advent of the COVID pandemic and the race to discover effective vaccines. The top-level uses of AI across the pharmaceutical sector are as follows Personalized Treatment/ Digital Therapeutics – AI is extensively being used to identify and assist drug developers to provide reliable and accurate insights for developing personalized therapeutics. Disease Identification/ Suggestive Treatment – With robust assessing abilities, AI is finding applications for the diagnosis of diseases ranging from Covid-19 to oncology to degeneration in the eyes. Drug Discovery and Manufacturing – AI assists in screening and comparing the predicted success rate of drug compounds based on biological factors with the results of the initial screening process such as rapid RNA and DNA quantification. Clinical Trials – The technology helps in identifying the most suitable candidate for the clinical trial on the basis of disease conditions, history, and additional attributes covering infection rates, ethnicity, and demographics to study the impact of the drug. The Way Ahead With growing applications in the development of novel therapeutic medications, shifting patient inclination toward personalized medicines, and the introduction of advanced medical fields such as gene therapy, AI is estimated to transform the pharmaceutical

Read More
PHARMA TECH

How Pharma Is Utilizing AI and Analytic Capabilities to Produce Positive Results

Article | July 7, 2022

Applications for AI are as diverse as the industries that employ them, and pharma has identified the particular varieties of AI that are most effective in attaining quicker, more fruitful results across a variety of business activities. In a world where every second counts, pharma and biotech businesses are under pressure to shorten the time to insight and deliver success. As a result, leading organizations quickly realize the potential of artificial intelligence (AI) as a crucial tool for advancing their operations. Leading pharma and biotech firms have realized the potential of AI and are utilizing it to boost productivity and innovation across the board, from production to drug discovery. Their procedures have significantly benefited from the application of machine learning (ML) and natural language processing (NLP), and the results are only becoming better because AI gets stronger and "smarter" the more data it processes. Advantages Pharma Industry Can Leverage Increased effectiveness across the spectrum in the pharmaceutical industry Drug discovery accelerates Superior disease surveillance, detection, and prevention Clinical trials with lower risk Greater insight into the client NLP is used to turn clinical trial data that is text-intensive and highly categorized into the data utilized in machine learning (ML) models, allowing the computer system to apply patterns to the data and generate insights. Clinical trial data is structured and enriched, making it possible to analyze and visualize the data for use in successful plans and strategies for clinical trial design, manufacturing, marketing, and other areas. Faster time to insight and improved business outcomes are the end results. A particularly true principle of machine learning applications is that the outcomes from using AI applications are only as reliable as the data itself. The Pharma Intelligence offering, which combines high-quality, extensive data from the pharmaceutical and biotechnology industries with advanced analytics and AI applications, has assisted customers with high-value products in resolving some of their most difficult key problems, including target prioritization, modalities innovation, competitive benchmarking, clinical trial design and deployment, and more.

Read More

Spotlight

SiriusDecisions

SiriusDecisions® is the leading global b-to-b research and advisory firm. We deliver actionable intelligence, strategic and operational frameworks, and personal guidance from experienced practitioners. Sales, marketing and product executives rely on SiriusDecisions® to contextualize problems and bring to light opportunities to drive sustainable growth. Our holistic solutions are founded on proprietary research, a deep understanding of b-to-b complexities, and the tenet that organizational alignment brings better outcomes. SiriusDecisions was acquired by Forrester (NASD: FORR) in January of 2019.

Related News

Inside plan to grow marijuana in Uganda

monitor | April 21, 2019

Different entities and individuals are fighting over the control of Uganda’s prospective medicinal cannabis industry, with a section of government officials reportedly fronting a number of companies to cash in on the multi-billion dollar business. Several entities with connections to already established companies in Europe and North America have been lined up by different officials as the government ponders a dive into the lucrative but dicey business. There is also a fight between several entities of government on who should take the lead in directing to the different investors lining up to engage in the lucrative business estimated to be worth $3b (about Shs11.1 trillion) when it commences. Among the entities that would be involved in licensing the entire chain are the ministries of Health, Agriculture, Justice and Constitutional Affairs and Internal Affairs; the National Drug Authority (NDA) and Uganda Investment Authority (UIA). The use of cannabis for recreational purposes such as smoking remains illegal in the country. Authorities are, however, exploring its production for medical purposes subject to authorisation by relevant government bodies in line with the Narcotic Drug and Pyschotropic Substances (Control) Act 2015.

Read More

Project aims to revive natural product discovery

eurekalert | April 23, 2019

The mid-20th century was the golden age of natural product discovery. Scientists discovered ground-breaking drugs, like penicillin and tetracycline, from sources in nature. But as the search for natural products continued, pharmaceutical companies kept finding the same products over and over again. By the early 2000s, most of these companies shut down their natural product discovery programs. At the same time, the era of genomics emerged. Instead of looking for natural products, scientists were now able to use genetic information to understand how natural products were made. This brought success in discovering new natural products, but only on a very small scale. Now, a new project aims to discover new natural products on a large scale by using synthetic biology and automation.

Read More

Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug

business-standard | April 23, 2019

Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. Hyderabad-based Dr Reddy’s Laboratories (DRL), which is betting big on the Chinese drug market, recently got an approval for a $1.6-billion anti-blood clotting drug from the Chinese regulator after an 11-year wait. Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. The launch of the product is still some time away. This would be DRL’s biggest product in China in terms of market potential. The drug is now undergoing generic equivalent assessment (China requires drugmakers to conduct bioequivalence studies).

Read More

Inside plan to grow marijuana in Uganda

monitor | April 21, 2019

Different entities and individuals are fighting over the control of Uganda’s prospective medicinal cannabis industry, with a section of government officials reportedly fronting a number of companies to cash in on the multi-billion dollar business. Several entities with connections to already established companies in Europe and North America have been lined up by different officials as the government ponders a dive into the lucrative but dicey business. There is also a fight between several entities of government on who should take the lead in directing to the different investors lining up to engage in the lucrative business estimated to be worth $3b (about Shs11.1 trillion) when it commences. Among the entities that would be involved in licensing the entire chain are the ministries of Health, Agriculture, Justice and Constitutional Affairs and Internal Affairs; the National Drug Authority (NDA) and Uganda Investment Authority (UIA). The use of cannabis for recreational purposes such as smoking remains illegal in the country. Authorities are, however, exploring its production for medical purposes subject to authorisation by relevant government bodies in line with the Narcotic Drug and Pyschotropic Substances (Control) Act 2015.

Read More

Project aims to revive natural product discovery

eurekalert | April 23, 2019

The mid-20th century was the golden age of natural product discovery. Scientists discovered ground-breaking drugs, like penicillin and tetracycline, from sources in nature. But as the search for natural products continued, pharmaceutical companies kept finding the same products over and over again. By the early 2000s, most of these companies shut down their natural product discovery programs. At the same time, the era of genomics emerged. Instead of looking for natural products, scientists were now able to use genetic information to understand how natural products were made. This brought success in discovering new natural products, but only on a very small scale. Now, a new project aims to discover new natural products on a large scale by using synthetic biology and automation.

Read More

Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug

business-standard | April 23, 2019

Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. Hyderabad-based Dr Reddy’s Laboratories (DRL), which is betting big on the Chinese drug market, recently got an approval for a $1.6-billion anti-blood clotting drug from the Chinese regulator after an 11-year wait. Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. The launch of the product is still some time away. This would be DRL’s biggest product in China in terms of market potential. The drug is now undergoing generic equivalent assessment (China requires drugmakers to conduct bioequivalence studies).

Read More

Events